Warning: The NCBI web site requires JavaScript to function. more...
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.
Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T.
Arthritis Res Ther. 2008;10(3):R67. Epub 2008 Jun 5.
Related citations
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
Arthritis Rheum. 2002 Dec;46(12):3143-50.
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J.
Arthritis Rheum. 2010 Apr;62(4):929-39.
The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.
Bresnihan B.
Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):17-20.
Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB.
Ann Rheum Dis. 2001 Jul;60(7):660-9.
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW, Gracie JA, Jongbloed S, Liew FY, McInnes IB.
Arthritis Rheum. 2005 Sep;52(9):2686-92.
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T.
Arthritis Rheum. 2004 Jun;50(6):1761-9.
Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients.
Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS.
Rheumatology (Oxford). 2003 Apr;42(4):541-8.
Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.
Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, et al.
Arthritis Rheum. 1995 Nov;38(11):1581-8.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators.
Lancet. 2008 Mar 22;371(9617):987-97.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.
Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H.
J Rheumatol. 2002 Nov;29(11):2288-98.
The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
BioDrugs. 2001;15(2):87-97. Review.
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.
Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, Panayi GS, Johnston JM.
Rheumatology (Oxford). 2000 Oct;39(10):1139-46.
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.
Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C.
Arthritis Rheum. 2009 Mar;60(3):738-49.
The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera.
Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, Yonezawa T, Saeki Y, Panayi GS, Pitzalis C, Kimura T.
Rheumatology (Oxford). 2002 Mar;41(3):329-37.
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.
Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U.
Arthritis Res. 2001;3(4):247-52. Epub 2001 Apr 10.
Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M.
Arthritis Rheum. 1996 Jul;39(7):1092-101.
Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy.
Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Ishida H, Shimizu M, Suemura M, McCloskey R, Kishimoto T.
J Clin Immunol. 1999 Sep;19(5):305-13.
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.
Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP.
Arthritis Rheum. 2008 Jul;58(7):1931-9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on